IFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - A preliminary study.

Simple item page
dc.contributor.authorMukherjee, Kalyan Kusum
dc.contributor.authorBose, Anamika
dc.contributor.authorGhosh, Diptendu
dc.contributor.authorSarkar, Koustav
dc.contributor.authorGoswami, Shyamal
dc.contributor.authorPal, Smarajit
dc.contributor.authorBiswas, Jaydip
dc.contributor.authorBaral, Rathindranath
dc.date.accessioned2013-01-24T07:15:41Z
dc.date.available2013-01-24T07:15:41Z
dc.date.issued2012-07
dc.description.abstractBackground & objectives: Interferon alpha 2b (IFNα2b) has been reported to regulate several immune functions efficiently to enhance the cytotoxic activity of NK and T cells towards various forms of tumours. The objective of the present study was to evaluate the efficacy of IFNα2b in overcoming disease induced and/or treatment associated imunosuppression of tongue squamous cell carcinoma (TSCC) patients undergoing chemotherapy for better clinical outcome. Methods: Seven TSCC patients under cisplatin + 5-fluorouracil chemotherapy in combination with IFNα2b were assessed for various immunohaematological parameters before treatment, after chemotherapy and after IFNα2b therapy. Results: Deterioration of the haematological and immune responses was detected in immunosuppressed TSCC patients after chemotherapy. IFNα2b treatment led to a recovery in these parameters in most of the patients. Greater number of T/NK cells and enhanced secretion of type 1 cytokines were also noted. Haematological complications were reduced after completion of the therapy. Immune- and haematostimulation were also observed in patients with partial response. No positive clinical response was detected in one patient. Interpretation & conclusions: IFNα2b appears to be an effective immunostimulator having clinical impact to combat the immunosuppression in TSCC patients. Successful immunostimulation by IFNα2b may help TSCC patients in clinical improvement. The findings of this preliminary study need to be confirmed on a large number of patients with TSCC.en_US
dc.identifier.citationMukherjee Kalyan Kusum, Bose Anamika, Ghosh Diptendu, Sarkar Koustav, Goswami Shyamal, Pal Smarajit, Biswas Jaydip, Baral Rathindranath. IFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - A preliminary study. Indian Journal of Medical Research. 2012 July; 136(1): 54-59.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/144659
dc.language.isoenen_US
dc.source.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461718/en_US
dc.subjectCytokineen_US
dc.subjectIFNa2ben_US
dc.subjectNK cellsen_US
dc.subjectT cellsen_US
dc.subjecttongue canceren_US
dc.subject.meshCarcinoma, Squamous Cell --drug therapy
dc.subject.meshCarcinoma, Squamous Cell --immunology
dc.subject.meshCisplatin --adverse effects
dc.subject.meshCisplatin --therapeutic use
dc.subject.meshFlow Cytometry
dc.subject.meshFluorouracil --adverse effects
dc.subject.meshFluorouracil --therapeutic use
dc.subject.meshHumans
dc.subject.meshImmune Tolerance --drug effects
dc.subject.meshInterferon-alpha --pharmacology
dc.subject.meshKiller Cells, Natural --drug effects
dc.subject.meshKiller Cells, Natural --immunology
dc.subject.meshRecombinant Proteins --pharmacology
dc.subject.meshT-Lymphocytes --drug effects
dc.subject.meshT-Lymphocytes --immunology
dc.subject.meshTongue Neoplasms --drug therapy
dc.subject.meshTongue Neoplasms --immunology
dc.titleIFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - A preliminary study.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmr2012v136n1p54.pdf
Size:
660.84 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Medical Research